Psychedelic medicine: a re-emerging therapeutic paradigm
1. Chwelos N, Blewett DB, Smith CM, et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol1959;20:577–90. [PubMed] [Google Scholar]
2. Yensen R, Di Leo , Rhead JC, et al. MDA-assisted psychotherapy with neurotic outpatients: A pilot study. J Nerv Ment Dis1976;163:233–45. [PubMed] [Google Scholar]
3. Krebs TS, Johansen PØ.Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol2012;26:994–1002. [PubMed] [Google Scholar]
4. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of LSD-assisted psychotherapy in subjects with anxiety associated with life-threatening diseases: a randomized active placebo-controlled phase 2 pilot study. J Nerv Ment Dis2014;202:513–20. [PMC free article] [PubMed] [Google Scholar]
5. Gasser P, Kirchner K, Passie T.LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J Psychopharmacol2015;29:57–68. [PubMed] [Google Scholar]
6. Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol2015;29:289–99. [PubMed] [Google Scholar]
7. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol2014;28:983–92. [PMC free article] [PubMed] [Google Scholar]
8. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry2011;68:71–8. [PubMed] [Google Scholar]
9. Thomas G, Lucas P, Capler NR, et al. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev2013;6:30–42. [PubMed] [Google Scholar]
10. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis1996;184:86–94. [PubMed] [Google Scholar]
11. Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol2015;25:483–92. [PubMed] [Google Scholar]
12. Bouso JC, González D, Fondevila S, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS ONE2012;7:e42421. [PMC free article] [PubMed] [Google Scholar]
13. Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend2010;111:257–61. [PubMed] [Google Scholar]
14. Halpern JH, Sherwood AR, Passie T, et al. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit2008;14:SR15–22. [PubMed] [Google Scholar]
15. Bogenschutz MP, Johnson MW.Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry2015. Mar.14. pii: S0278-5846(15)00051-2. [Google Scholar]
16. Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol2011;25:439–52. [PMC free article] [PubMed] [Google Scholar]
17. Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol2013;27:28–39. [PMC free article] [PubMed] [Google Scholar]
18. Oehen P, Traber R, Widmer V, et al. A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol2013;27:40–52. [PubMed] [Google Scholar]
19. Nichols DE.Hallucinogens. Pharmacol Ther2004;101:131–81. [PubMed] [Google Scholar]
20. Schultes RE, Hofmann A, Rätsch C.Plants of the gods: their sacred, healing, and hallucinogenic powers. Rochester (VT): Healing Arts Press; 2001. [Google Scholar]
21. Nichols DE.Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens — identification of a new therapeutic class: entactogens. J Psychoactive Drugs1986;18:305–13. [PubMed] [Google Scholar]
22. Danforth AL, Struble CM, Yazar-Klosinski B, et al. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol PsychiatryMar.25. pii: S0278-5846(15)00060-3. [Google Scholar]
23. Dyck E.Psychedelic psychiatry: LSD from clinic to campus. Baltimore: Johns Hopkins University Press; 2008. [Google Scholar]
24. Garcia-Romeu A, Griffiths RR, Johnson MW.Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev2014;7:157–64. [PMC free article] [PubMed] [Google Scholar]
25. Rush B.Evaluating the therapeutic potential of ayahuasca for substance use problems. Proceedings of the Second International Psychedelic Science 2013; Apr. 18–23Berkeley (CA): Multidisciplinary Association for Psychedelic Studies; 2013. [Google Scholar]
26. Loizaga-Velder A, Verres R.Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence — qualitative results. J Psychoactive Drugs2014;46:63–72. [PubMed] [Google Scholar]
27. Tupper KW, Labate BC.Ayahuasca, psychedelic studies and health sciences: the politics of knowledge and inquiry into an Amazonian plant brew. Curr Drug Abuse Rev2014;7:71–80. [PubMed] [Google Scholar]
28. Oram M.Efficacy and enlightenment: LSD psychotherapy and the drug amendment of 1962. J Hist Med Allied Sci2014;69:221–50. [PubMed] [Google Scholar]
29. Johnson M, Richards WA, Griffiths RR.Human hallucinogen research: guidelines for safety. J Psychopharmacol2008;22:603–20. [PMC free article] [PubMed] [Google Scholar]
30. Nutt DJ, King LA, Nichols DE.Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci2013;14:577–85. [PubMed] [Google Scholar]
31. Meyerhoefer MM.Serotonergic hallucinogens. In: Johnson BA, editor. , editor. Addiction medicine: science and practice. New York: Springer; 2011: 585–602. [Google Scholar]
32. Abraham HD, Aldridge AM, Gogia P.The psychopharmacology of hallucinogens. Neuropsychopharmacology1996;14:285–98. [PubMed] [Google Scholar]
33. Halpern JH, Pope HG.Hallucinogen persisting perception disorder: What do we know after 50 years?Drug Alcohol Depend2003;69:109–19. [PubMed] [Google Scholar]
34. Halpern JH, Pope HG.Do hallucinogens cause residual neuropsychological toxicity?Drug Alcohol Depend1999;53:247–56. [PubMed] [Google Scholar]
35. Hendricks PS, Thorne CB, Clark CB, et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol2015;29:280–8. [PubMed] [Google Scholar]
36. Johnson MW, Sewell RA, Griffiths RR.Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend2012;123:132–40. [PMC free article] [PubMed] [Google Scholar]
37. Doblin R, Greer G, Holland J, et al. A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research. Hum Psychopharmacol2014;29:105–8. [PubMed] [Google Scholar]
38. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet2009;373:2223–33. [PubMed] [Google Scholar]
39. Whiteford HA, Rehm LDJ, Baxter AJ, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease study 2010. Lancet2013;382:1575–86. [PubMed] [Google Scholar]
40. Nutt D, King LA, Saulsbury W, et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet2007;369:1047–53. [PubMed] [Google Scholar]
Magic Mushrooms As Medicine? Johns Hopkins Scientists Launch Center For Psychedelic Research. Say Psychedelics Could Treat Alzheimer’s, Depression And Addiction
Just a few decades ago, the approach would have been unfathomable to many. Using psychedelic drugs to treat people with PTSD? Depression? Addiction? To make them stop smoking? To perhaps treat Alzheimer’s? Wow. Just say no.
Weren’t these the drugs we were told growing up gave you emotional disorders? But times have changed, and today, as with so many other cultural shifts, people are taking a second look at some of the things considered taboo not so long ago.
And it just could be that the same generation that popularized the drugs could benefit from their therapeutic potential.
Roland R. Griffiths, Ph.D., a psychopharmacologist and professor in the Department of Psychiatry and Behavioral Sciences and the Department of Neuroscience at the Johns Hopkins University School of Medicine, said in an interview that the approach could offer “an entirely new paradigm for treating psychiatric disorders.”
He should know. Griffiths initiated the psilocybin research program at Johns Hopkins almost 20 years ago and led studies investigating the effects of its use by healthy volunteers. His research group at Johns Hopkins was the first to obtain regulatory approval in the U.S.
to re-initiate research with psychedelics in psychedelic-naïve healthy volunteers in 2000.
Griffiths said his group’s 2006 publication in the journal Psychopharmacology on psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide.
Roland Griffiths, Ph.D., director, Center for Psychedelic and Consciousness Research at Johns … [+] Hopkins Medicine.
(Photo courtesy of Center for Psychedelic and Consciousness Research)
Since then, Griffiths and his team have published several groundbreaking studies in more than 60 peer-reviewed articles in scientific journals. In fact, scientists at Johns Hopkins have administered psilocybin to over 350 healthy volunteers or patients over the past 19 years in some 700 sessions.
Griffiths will head up the new Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine. The first of its kind in the U.S.
and the largest research center of its kind in the world, the center is being funded initially by a $17 million donation from a group of private donors to advance the emerging field of psychedelics for therapies and wellness.
The center will house a team of six faculty neuroscientists, experimental psychologists and clinicians with expertise in psychedelic science, as well as five postdoctoral scientists. Graduate and medical students who want to work in psychedelic science, but have had few avenues to study in such a field, will be trained at the center.
“We have to take braver and bolder steps if we want to help those suffering from chronic illness, addiction and mental health challenges,” Alex Cohen, president of the Steven & Alexandra Cohen Foundation and a center-funder, said in a statement. “By investing in the Johns Hopkins center, we are investing in the hope that researchers will keep proving the benefits of psychedelics — and people will have new ways to heal.”
Psychedelics are a class of pharmacological compounds that produce unique and profound changes of consciousness. The most common psychedelics are psilocybin, , LSD (lysergic acid diethylamide), DMT (dimethyltryptamine), and mescaline. Much of Griffiths’ work is focused on psilocybin, the chemical found in so-called magic mushrooms.
Although research with these compounds began in the 1950s and 1960s in America, Griffiths said it was the “cultural trauma” of the psychedelic 60s—which included some adverse effects of the compounds—that ended it in the early 1970s. The unfavorable media coverage that ensued resulted in misperceptions of the risks of the drugs and highly restrictive regulations.
There are no federal funds being allocated to the new center. “There has been almost no funding for [psychedelic therapeutic research in people] because we are stuck in the mindset of the 1960s,” Griffiths said. “Psychedelics were demonized.
Their use was associated with the anti-war and anti-establishment movements of the 1960s and viewed as culturally disruptive. The sensationalistic media coverage established a narrative that overestimated risks that was soaked up by the culture.
It takes a long time to dispel such a narrative.”
With the Center for Psychedelic and Consciousness Research, Johns Hopkins reports it is the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.
“Research by us and others suggests therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression.
Studying healthy volunteers has also advanced our understanding of the enduring positive effects of psilocybin and provided unique insight into neurophysiological mechanisms of action, with implications for understanding consciousness and optimizing therapeutic and non-therapeutic enduring positive effects,” the center reports.
“There is much work to be done,” Griffiths said, adding that researchers want to next study the effects of psychedelics in people with early Alzheimer’s disease.
“To the extent that these drugs produce neuroplasticity, there may be some enduring effects on cognitive process,” he said.
That is in the future, he said, but for now, at least they know they can help the depression that comes with an Alzheimer’s diagnosis.
Griffiths said researchers have demonstrated in one treatment session with psychedelics what years of psychotropic drugs and counseling have not been able to accomplish. He compared psychedelic treatments for psychiatric problems to a curative surgical procedure (e.g.
joint replacement)—a one-time treatment that changes everything. “Many in the psychiatric community are baffled by this approach because we do not have any acute treatments that produce such robust and enduring therapeutic effects.
Frankly, it seems too unbelievable to be true, but yet the results to date suggests such efficacy,” he said.
People who have been treated with psilocybin often rate their encounters with psilocybin as among the “most personally meaningful experiences of their entire lives,” Griffiths said.
“It is fundamentally different than any other psychoactive drug. Because these experiences occur in most people, studies often look very similar to naturally-occurring experiences, and they appear to be biologically normal.
That is, we seem to be wired to have such experiences.”
“Some would hold that we were evolutionarily selected for such experiences because it results in some survival advantage.” Griffiths says that some people interpret the experience as an encounter with ultimate reality or with God.
And the drugs seem to offer neuroplasticity, or the ability of the brain to change, he said, allowing people to get the habitual ruts they have put themselves in as new neuropathways are formed. Griffiths said people claim that “it feels a home-coming or an epiphany that allows them to rewrite the narrative of their lives.”
Griffiths said he has administered psilocybin to individuals who have received a life-threatening diagnosis of cancer and individuals with treatment-resistant depression. “There were large and enduring decreases in their depression, and it endured past six months,” he said.
And some 80% of patients who have been treated for nicotine addiction are still smoke-free six months later, he said. There are other investigators looking at alcohol and cocaine addiction.
And other notable educational institutions are studying the possibilities of therapy with psychedelics, he said, including New York University (NYU), Yale University (YU), University of Alabama at Birmingham (UAB), University of California, Los Angeles (UCLA), University of California, San Fransisco (UCSF) and University of Wisconsin-Madison (UW-Madison).
Griffiths said that researchers are beginning to have hope that the compounds can be used in many more ways in a variety of maladies. “It appears as though the effects may be transdiagnostic—that they may be able to treat a variety of different disease entities including psychological and behavioral disorders,” he said.
For now, the center will focus on how psychedelics affect behavior, brain function, learning and memory, the brain’s biology and mood, Johns Hopkins announced last week.
“Studies of psilocybin in patients will determine its effectiveness as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to individual patients’ specific needs.”
Griffiths said volunteers for Johns Hopkins’ studies have been thoroughly screened, and he discourages people from attempting to self-medicate with psychedelics on their own. The center’s studies are done under carefully controlled circumstances, with known doses and trained therapists at participants’ sides for after care.
He said the concentration of street drugs is unknown, they could contain other contaminants, and some chemicals may be toxic and severely dangerous.
Additionally, Griffiths emphasized that not everyone should receive these drugs.
People who are prone to psychosis, such as schizophrenia, and other serious psychiatric conditions, may be vulnerable to enduring adverse effects.
Furthermore, there is concern that individuals may put themselves or others at risk by taking psychedelics on their own. “In a clinical setting, we can mitigate those risks,” he said.
According to officials, the new center’s operational expenses for the first five years will be covered by private funding from the Steven & Alexandra Cohen Foundation and four philanthropists: Tim Ferriss (author and technology investor), Matt Mullenweg (co-founder of WordPress), Blake Mycoskie (founder of TOMS, a shoe and accessory brand) and Craig Nerenberg (investor).
James Potash, M.D. called the investors “enlightened” in a statement. “This center will allow our enormously talented faculty to focus extensively on psychedelic research, where their passions lie and where promising new horizons beckon,” the Henry Phipps Professor and director of the Department of Psychiatry and Behavioral Sciences at Johns Hopkins said.